BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

Argenx SE

Отворен

СекторЗдравеопазване

533 0.53

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

523.6

Максимум

534.4

Ключови измерители

By Trading Economics

Приходи

751M

836M

Продажби

730M

1.3B

P/E

Средно за сектора

46.72

57.333

EPS

0.72

Марж на печалбата

64.112

Служители

1,599

EBITDA

37M

126M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

-2.07% downside

Дивиденти

By Dow Jones

Следващи печалби

8.05.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-4.3B

32B

Предишно отваряне

532.47

Предишно затваряне

533

Argenx SE Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

10.04.2025 г., 23:44 ч. UTC

Горещи акции

Stocks to Watch: Jacobs Solutions, Argenx

10.04.2025 г., 23:39 ч. UTC

Значими двигатели на пазара

Argenx ADRs Gain, FDA Approves New Delivery Method of Existing Autoimmune Disease Treatment

Сравнение с други в отрасъла

Ценова промяна

Argenx SE Прогноза

Ценова цел

By TipRanks

-2.07% надолу

12-месечна прогноза

Среден 438.33 EUR  -2.07%

Висок 545 EUR

Нисък 223 EUR

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Argenx SE през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

6 ratings

5

Купи

0

Задържане

1

Продай

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Argenx SE

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.